Rosenberg, Jonathan E.
Hahn, Noah M.
Regan, Meredith M.
Werner, Lillian
Alva, Ajjai
George, Saby
Picus, Joel
Alter, Robert
Balar, Arjun
Hoffman-Censits, Jean
Grivas, Petros
Lauer, Richard
Guancial, Elizabeth A.
Hoimes, Christopher
Sonpavde, Guru
Albany, Constantine
Stein, Mark N.
Breen, Tim
Jacobs, Cindy
Anderson, Kirsten
Bellmunt, Joaquim
Lalani, Aly-Khan A.
Pal, Sumanta
Choueiri, Toni K. http://orcid.org/0000-0002-9201-3217
Article History
Received: 12 October 2017
Revised: 23 March 2018
Accepted: 28 March 2018
First Online: 16 May 2018
Conflict of interest
: J.E.R. reports personal fees from OncoGenex during the conduct of the study; personal fees from Merck, BMS, Eli Lilly, AstraZeneca, EMD Serono, Inovio, Agensys, Genentech/Roche, Seattle Genetics, Sanofi, outside the submitted work. N.M.H. reports research support to the institution from Novartis, OncoGenex, Mirati, Merck, Genentech, Bristol-Myers Squibb, Heat Biologics, Acerta, AstraZeneca, and Prinicipia Biopharma; consulting support from OncoGenex, AstraZeneca, Merck, Bristol-Myers Squibb, Genentech, Inovio, Principia Biopharma, Champions Oncology, Health Advances, Taris Biomedical, and Seattle Genetics. M.M.R. reports grants from Hoosier Cancer Research Network during the conduct of the study. S.G. reports grants from BMS, Novartis, Bayer, Agensys, Merck, Pfizer, and Celldex during the conduct of the study; personal fees from AstraZeneca, Bristol-Myers Squibb, Bayer, Exelixis, Novartis, and Pfizer, outside the submitted work. J.P. reports institutional research funding from OncoGenex and Hoosier Cancer Research Network. A.B. reports research support to the institution from Merck, Genentech, and AstraZeneca; consulting support from AstraZeneca, Merck, Genentech, Pfizer/EMD Serono, and Cerulian Pharma. J.H.-C. reports grants and personal fees from Genentech; non-financial support from Genentech; personal fees from Clovis Oncology, Novartis, Merck, and Foundation Medicine, outside the submitted work. P.G. reports consulting with Genentech, Bayer, Dendreon, Bristol-Myers Squibb, Merck, Exelixis, AstraZeneca, Clovis Oncology, and EMD Serono; also participated in unbranded educational program with Genentech and Bristol-Myers Squibb. G.S. reports grants from Boehringer-Ingelheim, Bayer, Onyx-Amgen, and Merck; consultancy fees from Pfizer, Genentech, Novartis, Argos, Merck, Sanofi, Agensys, Clinical Care Options, Astrazeneca, Uptodate, Biotheranostics, Exelixis, Bristol-Myers Squibb, Janssen, Amgen, and Eisai; personal fees from NCCN (National Comprehensive Cancer Network). T.B. is a Hoosier Cancer Research Network employee. C.J. and K.A. are OncoGenex employees. J.B. reports research support from Novartis and Sanofi; consulting support from OncoGenex, AstraZeneca, Merck, Bristol-Myers Squibb, Genentech, Inovio, Champions Oncology, Seattle Genetics, and Pierre Fabre. T.K.C. reports institutional research funding from Pfizer, Exelixis, BMS, and Novartis; advisory roles at Pfizer, Novartis, Genentech, Merck, BMS, and Bayer. The remaining authors L.W., A.A., R.A., R.L., E.A.G., C.H., C.A., M.N.S., A.A.L., and S.P. declare no competing interests.
: All data and materials are available upon request.
: The study was approved by the institutional review boards and/or ethics committee at every enrolling center and was conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helsinki. The study was reviewed every 6 months by the Data Safety Monitoring Board of the Dana-Farber/Harvard Cancer Center.